📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
SMS Pharma Q3FY26 PAT Grows 29% YoY to ₹23.5 Cr; EBITDA Margins Cross 20%
SMS Pharmaceuticals reported a strong Q3FY26 with revenue growing 21% YoY to ₹210.45 crore, driven by volume growth in key APIs. Net profit (PAT) increased by 29% YoY to ₹23.47 crore, while EBITDA margins improved to 20.74% due to backward integration benefits. The company achieved its annual target of 10 filings ahead of schedule and is on track with its ₹280 crore capex plan. Management maintained a positive outlook for FY26, targeting 20% revenue growth and sustained margins.
Key Highlights
Revenue from operations grew 21% YoY to ₹210.45 crore in Q3FY26.
PAT for 9MFY26 surged 42% YoY to ₹69.27 crore, reflecting strong operational leverage.
EBITDA margins expanded by 158 bps YoY to 20.74%, supported by backward integration.
Significant 9MFY26 growth of 85% each in ARV, Anti-epileptic, and Anti-anginal therapeutic segments.
₹280 crore capacity expansion programme is on track for completion by FY27.
💼 Action for Investors
Investors should monitor the company's progress on its ₹280 crore capex plan and its ability to maintain the 20% EBITDA margin guidance. The strong growth in niche therapeutic areas and early R&D filings suggest a robust future pipeline.
SMS Pharma Q3 FY26 Revenue up 21% YoY to ₹210 Cr; PAT grows 29% to ₹23.5 Cr
SMS Pharmaceuticals reported a strong Q3 FY26 with revenue growing 21% YoY to ₹210.45 crore, driven by volume growth in key APIs. EBITDA margins improved to 21% from 19% YoY, aided by operating leverage and a better product mix. The company is on track to achieve its 20% revenue growth guidance for FY26 and is progressing with a ₹280 crore capex plan. Net profit for the nine-month period grew significantly by 42% YoY to ₹69.27 crore.
Key Highlights
Revenue from operations increased 21% YoY to ₹210.45 crore in Q3 FY26
EBITDA grew 31% YoY to ₹44 crore with margins expanding 158 bps to 21%
PAT after associate profit rose 29% YoY to ₹23.47 crore
Company is executing a ₹280 crore capex program to be completed by FY27
High-value products now contribute 45% of the portfolio, supporting gross margin expansion
💼 Action for Investors
Investors should monitor the progress of the ₹280 crore capex and the company's ability to maintain 20%+ margins. The stock remains attractive given the 42% 9M PAT growth and leadership in key API segments.
SMS Pharma Reports Zero Deviation in Utilization of Rs 114.30 Cr Raised via Warrants
SMS Pharmaceuticals has confirmed no deviation in the utilization of Rs 114.30 crores raised through a preferential issue of 90 lakh warrants. As of December 31, 2025, the company has utilized Rs 80.93 crores, primarily focusing on capital expenditure for production expansion and backward integration. A sum of Rs 33.35 crores has been temporarily deployed toward working capital to reduce finance costs, which the Audit Committee has advised be re-transferred for project execution as needed. The company is progressing with its plan to set up new production blocks for Key Starting Materials (KSM).
Key Highlights
Total issue size of Rs 114.30 crores fully raised following conversion of 90,00,000 warrants.
Cumulative utilization of funds stands at Rs 80.93 crores as of December 31, 2025.
Rs 48.05 crores utilized for CapEx and expansion of production capacities against an allocation of Rs 62.87 crores.
Temporary deployment of Rs 33.35 crores in working capital to optimize finance costs pending project execution.
Funds are being directed toward backward integration of Key Starting Materials (KSM) for existing and pipeline products.
💼 Action for Investors
Investors should track the completion of the production capacity expansion and KSM backward integration, as these are key to long-term margin improvement. The temporary use of funds for working capital is a standard treasury management practice and does not indicate a change in the company's strategic objectives.
SMSPHARMA Q3 Net Profit Rises 29% YoY to ₹23.47 Cr; Board OKs ₹7 Cr Subsidiary Investment
SMS Pharmaceuticals reported a strong year-on-year performance for Q3 FY26, with consolidated revenue growing 21.4% to ₹210.45 crore compared to ₹173.35 crore in the same quarter last year. Net profit for the quarter stood at ₹23.47 crore, a significant 28.7% increase from ₹18.24 crore YoY, although it saw a slight sequential dip from ₹25.31 crore in Q2. For the nine-month period, the company demonstrated robust growth with profits surging 42% to ₹69.28 crore. Additionally, the board approved a strategic investment of up to ₹7 crore in its subsidiary, SMS Peptides Private Limited, to strengthen its presence in the peptide segment.
Key Highlights
Consolidated Revenue from Operations grew 21.4% YoY to ₹210.45 crore in Q3 FY26.
Net Profit after tax increased by 28.7% YoY to ₹23.47 crore.
Nine-month (9M FY26) Net Profit reached ₹69.28 crore, a 41.9% increase over 9M FY25.
Board approved a further investment of up to ₹7 crore in subsidiary SMS Peptides Private Limited.
Basic EPS for the quarter improved to ₹2.59 from ₹2.15 in the previous year's corresponding quarter.
💼 Action for Investors
Investors should take note of the strong year-on-year growth and the strategic focus on the peptide segment. While there was a minor sequential decline, the overall nine-month trajectory remains robust, suggesting healthy operational momentum.
SMSPHARMA Q3 Net Profit Rises 29% YoY to ₹23.47 Cr; To Invest ₹7 Cr in Peptide Subsidiary
SMS Pharmaceuticals reported a strong year-on-year performance for the quarter ended December 31, 2025, with consolidated revenue growing 21.4% to ₹210.45 crore. Net profit for the quarter increased by 28.7% YoY to ₹23.47 crore, although it saw a sequential decline of 7.3% from the previous quarter. The company's nine-month performance remains robust, with net profit jumping nearly 42% compared to the same period last year. Additionally, the board approved a strategic investment of up to ₹7 crore in its subsidiary, SMS Peptides Private Limited, to expand its specialized portfolio.
Key Highlights
Consolidated Revenue from operations grew 21.4% YoY to ₹210.45 crore from ₹173.35 crore.
Net Profit after tax increased 28.7% YoY to ₹23.47 crore compared to ₹18.24 crore in Q3 FY25.
Nine-month (9M FY26) Net Profit reached ₹69.28 crore, a 41.9% increase over ₹48.82 crore in 9M FY25.
Board approved a fresh investment of up to ₹7 crore in subsidiary SMS Peptides Private Limited via equity.
Earnings Per Share (EPS) improved to ₹2.59 for the quarter, up from ₹2.15 in the year-ago period.
💼 Action for Investors
Investors should take note of the strong year-on-year growth and the company's move to further capitalize on its peptide subsidiary. While the sequential dip in revenue warrants monitoring, the overall nine-month growth trajectory remains healthy.
SMS Pharma Incorporates Wholly Owned Subsidiary SMS coLab for Greenfield Expansion
SMS Pharmaceuticals has successfully incorporated a new wholly owned subsidiary, SMS coLab Private Limited, as of December 23, 2025. This new entity is established as a greenfield project to focus on the research, development, and manufacturing of pharmaceutical products in new therapeutic categories. The company invested an initial cash consideration of Rs. 1,00,000 for a 100% equity stake, with an authorized capital of Rs. 15,00,000. This strategic move aims to expand the company's footprint in the formulations sector and enhance its global market reach.
Key Highlights
Incorporation of 'SMS coLab Private Limited' as a 100% subsidiary on December 23, 2025.
Initial paid-up capital of Rs. 1,00,000 with an authorized capital of Rs. 15,00,000.
Subsidiary to focus on greenfield projects in new therapeutic categories and R&D.
Business scope includes manufacturing, marketing, and global distribution of APIs and formulations.
The move is intended to establish strategic partnerships and joint ventures globally.
💼 Action for Investors
Investors should view this as a long-term growth signal and monitor future CAPEX announcements related to this greenfield project. No immediate impact on earnings is expected as the subsidiary is yet to commence operations.
SMS Pharma: USFDA inspects Vizag facility, issues one minor observation
SMS Pharmaceuticals Limited announced the successful completion of a USFDA inspection at its API manufacturing facility in Visakhapatnam from December 8 to December 12, 2025. The inspection concluded with one minor procedural observation in Form 483, which does not relate to data integrity. The Vizag facility is a 3,000 KL flagship API manufacturing facility with multiple global regulatory approvals. This marks the 4th inspection for this facility and the 12th across SMS Pharma's manufacturing sites.
Key Highlights
USFDA inspection completed at Vizag facility from December 8 to December 12, 2025
One minor observation in Form 483 issued by USFDA
Vizag facility is a 3,000 KL API manufacturing facility
Facility has 12 regulatory approvals including USFDA, WHO-GMP and EU-GMP
This is the 4th USFDA inspection for the Vizag facility
💼 Action for Investors
Investors should monitor the company's response to the USFDA observation and any subsequent updates. The successful inspection supports continued API supply to international markets.